Sunday, October 12, 2025

Latest

Cresco Labs: Analyst Q4 2020 Consensus Expectations

Cresco Labs (CSE: CL) announced that they will be reporting their fourth quarter and year-end financials pre-market on March 25th. Analysts have a consensus C$22.22 12-month price target on the company, via a total of 16 analysts, with four analysts having a strong buy rating and the other 11 have buy ratings and one analyst has a hold rating. The street high comes from Stifel-GMP with a C$36 price target, and the lowest target comes from Roth Capital with a C$17.50 price target.

Sixteen analysts have revenue estimates for the fourth quarter. The mean between all 16 is U$161.38 million; this number has been revised downwards from U$162.50 million at the start of the year. Needham & Co currently has the highest revenue estimate with U$167.8 million, while the lowest comes from Piper Sandler with a U$156.1 million estimate.

For the full year, the average revenue estimate between 16 analysts is currently U$475.52 million. This number has been revised downwards from U$475.52 million at the start of the year. The street high comes from Needham & Co with a U$481.70 full-year revenue estimate, while the lowest comes from Piper Sandler with a U$470 million estimate.

Onto EBITDA estimates, there are currently 14 analysts who have fourth-quarter EBITDA estimates. The mean is currently U$48.06 million, with this number roughly the same since the start of the year. Street high goes to Needham & Co with a U$52,14 million EBITDA estimate and the lowest being ATB Capital with a U$42.20 million estimate.

For the full year, the current EBITDA mean across 12 analysts is U$114.13 million. This number is roughly the same since the start of the year. Needham & Co currently has the highest full-year estimate at U$118.21 million and the lowest being Benchmark with a U$158 million estimate.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Atlas Salt: The Updated Feasibility Study

Why Sage Potash Could Be America’s Next Fertilizer Powerhouse

GOLD: Leadership Shakeup Among Majors. A Sign Of Something To Come?

Recommended

First Majestic Posts Record Quarterly Silver Production In Q3

Nord Precious Metals Produces High Grade Silver Concentrate From Tailings

Related News

NG Energy: Beacon Maintains $2.80 Price Target After Sinu-9 Discovery

Yesterday, NG Energy (TSXV: GASX) announced that it had conducted two successful drillstem tests and...

Wednesday, August 3, 2022, 04:29:00 PM

Canaccord: Canopy USA Transaction Is An Overall Positive

Canopy Growth (TSX: WEED) earlier this week revealed that it would be restructuring its US...

Thursday, October 27, 2022, 03:06:00 PM

Canaccord: IAMGOLD Has “Few Desirable Options To Plug Funding Gap”

On May 3, IAMGOLD Corporation (TSX: IMG) reported its first quarter results for 2022. The...

Thursday, May 5, 2022, 02:24:00 PM

Raymond James Calls Indiva 75% Undervalued, Gives 243% Upside Target

This week, Raymond James initiated coverage on Indiva Limited (TSXV: NDVA) with a $1.75 price...

Thursday, September 9, 2021, 03:42:00 PM

Cresco Labs Posts 1.8% Sequential Revenue Growth In Second Quarter

Cresco Labs (CSE: CL) was the latest cannabis operator to report earnings this morning for...

Wednesday, August 17, 2022, 08:15:24 AM